AstraZeneca enters into agreement to resolve Faslodex patent litigation in the US

Regulatory News Service

13 July 2016 at 07:00

This announcement contains inside information


AstraZeneca today announced that it has entered into an agreement with Sandoz, Inc. and affiliates (“Sandoz”) to resolve Faslodex (fulvestrant) patent litigation in the US relating to Sandoz’s generic fulvestrant product, for which it is seeking FDA approval.

The US Faslodex patents in question are due to expire in January 2021, with paediatric exclusivity continuing until July 2021. On 12 July 2016, the United States District Court for the District of New Jersey entered a consent judgment filed by AstraZeneca and Sandoz, which includes an injunction preventing Sandoz from launching a generic fulvestrant product until 25 March 2019, or earlier in some circumstances.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com    

CONTACTS

Media Enquiries

 

 

 

 

Neil Burrows

UK/Global

+44 7842 350541

Vanessa Rhodes

UK/Global

+44 7880 400690

Karen Birmingham

UK/Global

+44 7818 524012

Rob Skelding

UK/Global

+44 7392 103298

Jacob Lund

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677

 

 

 

 

Investor Enquiries

 

 

     

UK

 

 

Thomas Kudsk Larsen

 

+44 7818 524185

Nick Stone

Respiratory and Autoimmunity

+44 7717 618834

Henry Wheeler

Oncology

+44 7788 354619

Craig Marks

Finance, Fixed Income, M&A

+44 7881 615764

Christer Gruvris

Infection and Neuroscience

+44 7827 836825

 

 

 

US

 

 

Lindsey Trickett

Cardiovascular and Metabolic Diseases

+1 240 543 7970

Mitch Chan

Oncology

+1 240 477 3771

Toll-free

 

+1 866 381 7277

 

Adrian Kemp
Company Secretary
AstraZeneca PLC

tags

  • Regulatory